Hoth Therapeutics, XTI Aerospace, and Immuneering are the 3 Penny Stocks to watch on January 9, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are defined as stocks that trade at or below $5 per share and have a market capitalization of below $300 million.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The Penny Stock Screener helps investors scan stocks based on numerous parameters, including Sector, Price Target Upside, Smart Score, Analyst Consensus, Dollar Volume, and Price Change.
We leveraged the tool to pick the top three penny stocks with the highest Dollar Volume as of the close on January 8, 2025. Simply put, Dollar Volume is the number of shares traded on a particular day multiplied by the day’s share price.
Hoth Therapeutics (HOTH) – Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for improving patients’ lives. On January 8, HOTH had a Dollar Volume of $952.75 million, while its stock price plunged by 16.7%.
Hoth shares have been trading wildly since January 7, when the company announced a 100% success rate in its Phase 2a Trial: HT-001. The clinical trial met primary efficacy endpoint results for combating cancer treatment skin toxicities. Shares skyrocketed over 178% on the news. Following this news, on January 8, Hoth denied all rumors that the company was seeking to raise additional capital through a public/private offering.
XTI Aerospace (XTIA) – XTI Aerospace is engaged in developing a six-seater passenger civilian fixed-wing vertical take-off and landing (VTOL) aircraft for the light and mid-size business aircraft market. The company seeks to reduce the “total trip time” by offering point-to-point air travel.
XTIA’s Dollar Volume stood at $304.18 million yesterday, while its share price collapsed by 55.7%. The stock price decline seems to be a reversal from Tuesday’s rally, when shares spiked over 29%. On January 7, XTIA announced a one-for-250 reverse stock split of its common stock to regain compliance with Nasdaq’s minimum bid price requirement. Shares are expected to start trading on a split-adjusted basis on January 10. Moreover, XTIA announced the offering of 363.64 million common shares priced “at the market” under Nasdaq rules, with the offering price of $0.055 per share.
Immuneering Corp. (IMRX) – Immuneering is a clinical-stage oncology company focused on developing more effective and better-tolerated therapies for cancer patients. Its lead product candidate is IMM-1-104, which is a once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors.
IMRX had a Dollar Volume of $190.97 million on January 8, accompanied by a stock price decline of 15.3%. Shares seem to have reversed the surge from Tuesday. On January 7, IMRX shares spiked over 58% on news of positive data updates from three pancreatic cancer arms of the ongoing Phase 2a trial of IMM-1-104. Plus, the company announced plans to expand the Phase 2a trial by including three additional combination arms. Investors reacted positively to this news.
To find more penny stocks like these, you can take a look at TipRanks’ Penny Stock Screener tool. It shows a list of all penny stocks, their price movement, and other vital data.
